CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $367,068 | -21.2% | 9,747 | -0.8% | 0.39% | -16.2% |
| Q2 2023 | $465,710 | +21.9% | 9,823 | -2.2% | 0.46% | -4.9% |
| Q1 2023 | $382,086 | -15.0% | 10,044 | -23.7% | 0.49% | -21.7% |
| Q4 2022 | $449,256 | -31.7% | 13,166 | +30.8% | 0.62% | -21.8% |
| Q3 2022 | $658,000 | +10.8% | 10,068 | -13.0% | 0.80% | +14.3% |
| Q2 2022 | $594,000 | +15.1% | 11,567 | +35.9% | 0.70% | +63.2% |
| Q1 2022 | $516,000 | -3.4% | 8,511 | +16.4% | 0.43% | -1.8% |
| Q4 2021 | $534,000 | -16.3% | 7,309 | +28.2% | 0.44% | -27.5% |
| Q3 2021 | $638,000 | -17.8% | 5,701 | +19.0% | 0.60% | -21.9% |
| Q2 2021 | $776,000 | +72.4% | 4,791 | +29.6% | 0.77% | +58.4% |
| Q1 2021 | $450,000 | +67.3% | 3,697 | +110.1% | 0.48% | +77.7% |
| Q4 2020 | $269,000 | – | 1,760 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |